What are the ASH recommendations for treatment of immune thrombocytopenic purpura (ITP) in patients at risk of bleeding?

Updated: Jun 28, 2019
  • Author: Craig M Kessler, MD, MACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

When one line of therapy (eg, corticosteroids, IVIg) has failed and the patient is at risk of bleeding, ASH suggests that the following treatments may be considered:

  • Thrombopoietin receptor agonists, in patients who have not undergone splenectomy
  • Rituximab, after failure of one line of medical therapy or splenectomy

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!